TABLE 2.
Organ | Hp+/+ | Hp−/− |
---|---|---|
Spleen | ||
Weight | 89.4 ± 11.4 mg | 58.8 ± 8.7 mga |
Total cell number | 113.7 ± 12.8 × 106 | 41.5 ± 5.2 × 106a |
B cells (B220+) | 69.0 ± 1.9 × 106 (60.7±1.8%) | 15.2 ± 1.1 × 106 (36.7±2.9%)a |
T cells (CD3+) | 27.8 ± 1.4 × 106 (24.4±1.4%) | 16.7 ± 1.1 × 106 (40.2±2.0%)a |
CD4+ CD25− | 13.9 ± 0.4 × 106 (12.2±1.1%) | 8.3 ± 1.4 × 106 (21.1±1.4%) |
CD4+ CD25+ | 1.4 ± 0.1 × 106 (1.2±0.1%) | 1.0 ± 0.1 × 106 (2.5±0.2%) |
CD8+ | 11.5 ± 0.6 × 106 (10.1±0.6%) | 7.1 ± 0.3 × 106 (17.0±0.8%) |
NK cells (Nk1.1+) | 2.8 ± 0.6% | 4.4 ± 0.3% |
Monocytes (CD11b+) | 4.3 ± 0.7% | 8.3 ± 1.2%a |
DC (CD11c+) | 1.7 ± 0.3% | 3.8 ± 0.3%a |
Thymus | ||
Weight | 53.1 ± 9.2 mg | 42.9 ± 6.4 mg |
Total cell number | 89.3 ± 14.1 × 106 | 77.4 ± 17.9 × 106 |
CD4− CD8− | 5.9 ± 0.6% | 12.2 ± 0.9%a |
CD4+ CD8+ | 80.5 ± 2.1% | 74.1 ± 1.7% |
CD4+ CD8− CD25− | 8.7 ± 0.8% | 6.6 ± 0.6% |
CD4+ CD8− CD25+ | 0.6 ± 0.1% | 0.9 ± 0.1% |
CD4− CD8+ | 5.0 ± 0.7% | 7.0 ± 0.7% |
CD3− CD4− CD8−b | (100%)b | (100%)b |
CD44+ CD25− | 6.8 ± 0.3% | 3.7 ± 0.3% |
CD44+ CD25+ | 5.1 ± 1.0% | 5.3 ± 0.5% |
CD44− CD25+ | 42.2 ± 2.3% | 60.3 ± 0.7%a |
CD44− CD25− | 45.9 ± 2.2% | 30.7 ± 0.6%a |
Lymph node | ||
Weight | 69 ± 8.7 mg | 54.7 ± 6.9 mg |
Total cell number | 60.9 ± 12.7 × 106 | 45.8 ± 9.7 × 106 |
B cells (B220+) | 32.2 ± 1.8% | 19.1 ± 2.0%a |
T cells (CD3+) | 51.2 ± 1.4% | 63.2 ± 3.1% |
CD4+ CD25− | 27.0 ± 1.4% | 24.1 ± 0.6% |
CD4+ CD25+ | 2.6 ± 0.2% | 1.9 ± 0.3% |
CD8+ | 19.6 ± 2.1% | 33.2 ± 2.5%a |
Bone marrow | ||
B220−IgM− | 49.2 ± 11.8% | 63.2 ± 8.9% |
B220+IgM− | 32.7 ± 11.8% | 25.0 ± 8.6% |
B220+IgM+ | 15.2 ± 3.4% | 8.7 ± 3.7%a |
Cellular composition of major lymphoid organs from age-matched (10-week) Hp−/− and Hp+/+ C57BL/6 mice (n = 7–10), as determined by well-defined markers for each cell type. The values represent means ± sem obtained by staining and flow cytometry analysis.
Statistically significant difference between Hp−/− and Hp+/+ mice.
Percentage of different stage thymocytes that are CD−CD4−CD8− have been reported as a percentage of the total CD3−CD4−CD8− population.